Astellas Pharma. has filed a patent for methods to detect target cell types within a cell population using indicators. The technology allows for sensitive detection of human embryonic stem cells in differentiated cell populations, ensuring safety before transplantation. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Detection of target cell type in cell population
The patent application (Publication Number: US20240026419A1) describes a method for confirming the absence of contaminating pluripotent stem cells in a preparation of differentiated cells derived from pluripotent stem cells. The method involves culturing the differentiated cells in a medium that maintains pluripotent stem cells in their pluripotent state, applying specific stains to detect embryonic stem cell markers indicative of contaminating pluripotent stem cells, and confirming the absence of such cells through microscopic observation. The method utilizes stains targeting various embryonic stem cell markers and can be applied to different types of pluripotent stem cells, including human cells, embryonal carcinoma cells, embryonic stem cells, and induced pluripotent stem cells.
Furthermore, the patent application details additional steps such as determining the approximate number of cells in the population, applying a third stain to detect another embryonic stem cell marker, and isolating retinal pigment epithelium (RPE) cells from the culture of differentiated cells. The method also includes culturing the differentiated cells on feeder cells, such as murine embryonic fibroblasts or human adult skin fibroblasts, to produce a population of RPE cells. Overall, the method provides a comprehensive approach to ensuring the purity of differentiated cell populations by confirming the absence of contaminating pluripotent stem cells through specific staining techniques and microscopic observation, thereby enhancing the quality and safety of cell-based therapies and research applications.
To know more about GlobalData’s detailed insights on Astellas Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
